Royalty Pharma plc (RPRX)
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Founded
2020
Number of Employees
89
Website
http://www.royaltypharma.com
Buyback
Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
$ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | - | $305 | $84 | $195 |
Average Price | - | - | - | - | - | - | - | - | - | $30.95 | $27.08 | $30.02 |
# Shares Purchased | - | - | - | - | - | - | - | - | - | 9,846 | 3,117 | 6,482 |
Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Return to Date | - | - | - | - | - | - | - | - | - | -12.8% | -0.3% | -10.1% |
S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | 7.4% | 19.4% |
Excess Total Return | - | - | - | - | - | - | - | - | - | -44.1% | -7.7% | -29.4% |
Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
Percentile Rank | - | - | - | - | - | - | - | - | - | 24% | 40% | 35% |
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)